Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN GLENMARK PHARMA/
LUPIN
 
P/E (TTM) x -31.6 40.8 - View Chart
P/BV x 2.9 6.0 47.9% View Chart
Dividend Yield % 0.3 0.2 105.2%  

Financials

 GLENMARK PHARMA   LUPIN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-23
LUPIN
Mar-23
GLENMARK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs487799 61.0%   
Low Rs349583 59.8%   
Sales per share (Unadj.) Rs460.4365.8 125.9%  
Earnings per share (Unadj.) Rs13.49.8 135.9%  
Cash flow per share (Unadj.) Rs35.029.2 120.0%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Avg Dividend yield %0.60.6 103.3%  
Book value per share (Unadj.) Rs335.1270.7 123.8%  
Shares outstanding (eoy) m282.17454.98 62.0%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.91.9 48.1%   
Avg P/E ratio x31.370.2 44.5%  
P/CF ratio (eoy) x11.923.7 50.4%  
Price / Book Value ratio x1.22.6 48.9%  
Dividend payout %18.740.7 46.0%   
Avg Mkt Cap Rs m117,953314,381 37.5%   
No. of employees `000NANA-   
Total wages/salary Rs m27,81030,872 90.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m129,901166,417 78.1%  
Other income Rs m3,1681,509 209.9%   
Total revenues Rs m133,069167,926 79.2%   
Gross profit Rs m15,12517,206 87.9%  
Depreciation Rs m6,1138,807 69.4%   
Interest Rs m3,4962,743 127.4%   
Profit before tax Rs m8,6857,165 121.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,9112,688 182.7%   
Profit after tax Rs m3,7744,477 84.3%  
Gross profit margin %11.610.3 112.6%  
Effective tax rate %56.537.5 150.7%   
Net profit margin %2.92.7 108.0%  
BALANCE SHEET DATA
Current assets Rs m98,737124,513 79.3%   
Current liabilities Rs m50,45592,654 54.5%   
Net working cap to sales %37.219.1 194.1%  
Current ratio x2.01.3 145.6%  
Inventory Days Days726 25.5%  
Debtors Days Days11598 117.2%  
Net fixed assets Rs m76,920103,490 74.3%   
Share capital Rs m282910 31.0%   
"Free" reserves Rs m94,281122,246 77.1%   
Net worth Rs m94,563123,156 76.8%   
Long term debt Rs m38,521275 14,002.7%   
Total assets Rs m175,658228,003 77.0%  
Interest coverage x3.53.6 96.5%   
Debt to equity ratio x0.40 18,236.6%  
Sales to assets ratio x0.70.7 101.3%   
Return on assets %4.13.2 130.7%  
Return on equity %4.03.6 109.8%  
Return on capital %9.28.0 114.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m46,46448,057 96.7%   
Fx outflow Rs m12,71221,752 58.4%   
Net fx Rs m33,75126,306 128.3%   
CASH FLOW
From Operations Rs m6,25418,972 33.0%  
From Investments Rs m-5,285-12,868 41.1%  
From Financial Activity Rs m-775-3,373 23.0%  
Net Cashflow Rs m3252,732 11.9%  

Share Holding

Indian Promoters % 46.7 46.8 99.8%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 34.7 45.8 75.6%  
FIIs % 23.7 16.1 147.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 53.0 100.7%  
Shareholders   209,931 281,542 74.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUN PHARMA    DIVIS LABORATORIES    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on Glenmark Pharma vs Lupin

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

Glenmark Pharma vs Lupin Share Price Performance

Period Glenmark Pharma Lupin S&P BSE HEALTHCARE
1-Day 0.02% 1.45% 1.44%
1-Month 5.79% 0.38% -0.50%
1-Year 114.21% 151.70% 62.23%
3-Year CAGR 27.76% 17.22% 18.26%
5-Year CAGR 8.18% 17.48% 19.85%

* Compound Annual Growth Rate

Here are more details on the Glenmark Pharma share price and the Lupin share price.

Moving on to shareholding structures...

The promoters of Glenmark Pharma hold a 46.7% stake in the company. In case of Lupin the stake stands at 47.0%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Glenmark Pharma and the shareholding pattern of Lupin.

Finally, a word on dividends...

In the most recent financial year, Glenmark Pharma paid a dividend of Rs 2.5 per share. This amounted to a Dividend Payout ratio of 18.7%.

Lupin paid Rs 4.0, and its dividend payout ratio stood at 40.7%.

You may visit here to review the dividend history of Glenmark Pharma, and the dividend history of Lupin.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine(10:30 am)

Asian markets traded lower, while the US stock indices ended higher overnight with the S&P 500 hitting a record closing high ahead of key economic data.